首页> The Lancet. Oncology> Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.

导出原文传递

翻译打印收藏纠错

第一作者： Hans,Wildiers

第一单位： Department of General Medical Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be.

作者： Hans,Wildiers ^[1] ; Konstantinos,Tryfonidis ^[2] ; Lissandra,Dal Lago ^[3] ; Peter,Vuylsteke ^[4] ; Giuseppe,Curigliano ^[5] ; Simon,Waters ^[6] ; Barbara,Brouwers ^[7] ; Sevilay,Altintas ^[8] ; Nathan,Touati ^[2] ; Fatima,Cardoso ^[9] ; Etienne,Brain ^[10]

作者单位： Department of General Medical Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be. ^[1] European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. ^[2] Department of Medicine, Institut Jules Bordet, Brussels, Belgium. ^[3] Centre Hospitalier Universitaire, Université Catholique de Louvain, Namur, Belgium. ^[4] Department of Hematology and Oncology, Division of Early Drug Development, University of Milano, Istituto Europeo di Oncologia, Milan, Italy. ^[5] Velindre Cancer Centre, Cardiff, UK. ^[6] Department of Medical Oncology, AZ Sint-Jan Hospital, Bruges, Belgium. ^[7] Department of Medical Oncology, Antwerp University Hospital, Antwerp, Belgium. ^[8] Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal. ^[9] Department of Medical Oncology, Institut Curie (Hôpital René Huguenin) Saint-Cloud, France. ^[10]